A bivalent live-attenuated vaccine candidate elicits protective immunity against human adenovirus types 4 and 7

References

• Prusinkiewicz MA, Mymryk JS. Metabolic reprogramming of the host cell by human adenovirus infection. Viruses. 2019 Feb 8;11(2):141.
   Web of Science ®Google Scholar
• Lynch III JP, Kajon AE. Adenovirus: epidemiology, global spread of novel serotypes, and advances in treatment and prevention. Semin Respir Crit Care Med. 2016 Aug;37(4):586–602.
   PubMed Web of Science ®Google Scholar
• Sandkovsky U, Vargas L, Florescu DF. Adenovirus: current epidemiology and emerging approaches to prevention and treatment. Curr Infect Dis Rep. 2014 Aug;16(8):416.
   PubMed Web of Science ®Google Scholar
• Schwartz KL, Richardson SE, MacGregor D, et al. Adenovirus-associated central nervous system disease in children. J Pediatr. 2019 Feb;205:130–137.
   Web of Science ®Google Scholar
• Kajon AE, Lamson DM, Bair CR, et al. Adenovirus type 4 respiratory infections among civilian adults, Northeastern United States, 2011–2015. Emerg Infect Dis. 2018 Feb;24(2):201–209.
   Web of Science ®Google Scholar
• Shachor-Meyouhas Y, Hadash A, Kra-Oz Z, et al. Adenovirus respiratory infection among immunocompetent patients in a pediatric intensive care unit during 10-year period: co-morbidity is common. Isr Med Assoc J. 2019 Sep;21(9):595–598.
   Web of Science ®Google Scholar
• Echavarria M. Adenoviruses in immunocompromised hosts. Clin Microbiol Rev. 2008 Oct;21(4):704–715.
   PubMed Web of Science ®Google Scholar
• Hoffman JA. Adenovirus infections in solid organ transplant recipients. Curr Opin Organ Transplant. 2009 Dec;14(6):625–633.
   Web of Science ®Google Scholar
• Gonzalez G, Bair CR, Lamson DM, et al. Genomic characterization of human adenovirus type 4 strains isolated worldwide since 1953 identifies two separable phylogroups evolving at different rates from their most recent common ancestor. Virology. 2019 Dec;538:11–23.
   Web of Science ®Google Scholar
• Purkayastha A, Su J, Carlisle S, et al. Genomic and bioinformatics analysis of HAdV-7, a human adenovirus of species B1 that causes acute respiratory disease: implications for vector development in human gene therapy. Virology. 2005 Feb 5;332(1):114–129.
   Web of Science ®Google Scholar
• De Conto F, Conversano F, Medici MC, et al. Epidemiology of human respiratory viruses in children with acute respiratory tract infection in a 3-year hospital-based survey in Northern Italy. Diagn Microbiol Infect Dis. 2019 Jul;94(3):260–267.
   Web of Science ®Google Scholar
• Heindl LM, Augustin AJ, Messmer EM, et al. ADenovirus initiative study in epidemiology (ADVISE)-results of a multicenter epidemiology study in Germany. Graefes Arch Clin Exp Ophthalmol. 2019 Jan;257(1):249–251.
   Web of Science ®Google Scholar
• Li J, Lu X, Sun Y, et al. A swimming pool-associated outbreak of pharyngoconjunctival fever caused by human adenovirus type 4 in Beijing, China. Int J Infect Dis. 2018 Oct;75:89–91.
   PubMed Web of Science ®Google Scholar
• Zhang J, Kang J, Dehghan S, et al. A survey of recent adenoviral respiratory pathogens in Hong Kong reveals emergent and recombinant human adenovirus type 4 (HAdV-E4) circulating in civilian populations. Viruses. 2019 Jan 31;11(2):129.
   PubMed Web of Science ®Google Scholar
• Coleman KK, Robie ER, Abdelgadir A, et al. Six decades of human adenovirus type 4 infections reviewed: increasing infections among civilians are a matter of concern. Clin Infect Dis. 2021 Aug 16;73(4):740–746.
   Web of Science ®Google Scholar
• Fu Y, Tang Z, Ye Z, et al. Human adenovirus type 7 infection causes a more severe disease than type 3. BMC Infect Dis. 2019 Jan 9;19(1):36.
   PubMed Web of Science ®Google Scholar
• Cai R, Mao N, Dai J, et al. Genetic variability of human adenovirus type 7 circulating in mainland China. PLoS One. 2020;15(4):e0232092.
   Web of Science ®Google Scholar
• Dudding BA, Top Jr FH, Winter PE, et al. Acute respiratory disease in military trainees: the adenovirus surveillance program, 1966–1971. Am J Epidemiol. 1973 Mar;97(3):187–198.
   Web of Science ®Google Scholar
• Hilleman MR. Epidemiology of adenovirus respiratory infections in military recruit populations. Ann N Y Acad Sci. 1957 Apr 19;67(8):262–272.
   Web of Science ®Google Scholar
• Hilleman MR. Efficacy of and indications for use of adenovirus vaccine. Am J Public Health Nations Health. 1958;48(February (2)):153–158.
   Web of Science ®Google Scholar
• Radin JM, Hawksworth AW, Blair PJ, et al. Dramatic decline of respiratory illness among US military recruits after the renewed use of adenovirus vaccines. Clin Infect Dis. 2014 Oct;59(7):962–968.
   Web of Science ®Google Scholar
• Choudhry A, Mathena J, Albano JD, et al. Safety evaluation of adenovirus type 4 and type 7 vaccine live, oral in military recruits. Vaccine. 2016 Aug 31;34(38):4558–4564.
   Web of Science ®Google Scholar
• Hoke CH J, Snyder CE J. History of the restoration of adenovirus type 4 and type 7 vaccine, live oral (adenovirus vaccine) in the context of the department of defense acquisition system. Vaccine. 2013 Mar 15;31(12):1623–1632.
   Web of Science ®Google Scholar
• Potter RN, Cantrell JA, Mallak CT, et al. Adenovirus-associated deaths in US military during postvaccination period, 1999–2010. Emerg Infect Dis. 2012 Mar;18(3):507–509.
   Web of Science ®Google Scholar
• Kuschner RA, Russell KL, Abuja M, et al. A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of the live, oral adenovirus type 4 and type 7 vaccine, in U.S. military recruits. Vaccine. 2013 Jun 19;31(28):2963–2971.
   Web of Science ®Google Scholar
• Broderick M, Myers C, Balansay M, et al. Adenovirus 4/7 vaccine's effect on disease rates is associated with disappearance of adenovirus on building surfaces at a military recruit base. Mil Med. 2017 Nov;182(11):e2069–e2072.
   Web of Science ®Google Scholar
• Lyons A, Longfield J, Kuschner R, et al. A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults. Vaccine. 2008 Jun 2;26(23):2890–2898.
   Web of Science ®Google Scholar
• McNeil MM, Paradowska-Stankiewicz I, Miller ER, et al. Adverse events following adenovirus type 4 and type 7 vaccine, live, oral in the vaccine adverse event reporting system (VAERS), United States, October 2011–July 2018. Vaccine. 2019 Oct 16;37(44):6760–6767.
   Web of Science ®Google Scholar
• Minor PD. Live attenuated vaccines: historical successes and current challenges. Virology. 2015 May;479–480:379–392.
   PubMed Web of Science ®Google Scholar
• Shah MS, Ashraf A, Rahman M, et al. A subunit vaccine against hydropericardium syndrome using adenovirus penton capsid protein. Vaccine. 2012 Nov 26;30(50):7153–7156.
   Web of Science ®Google Scholar
• Hu K, Fu M, Guan X, et al. Penton base induces better protective immune responses than fiber and hexon as a subunit vaccine candidate against adenoviruses. Vaccine. 2018 Jul 5;36(29):4287–4297.
   PubMed Web of Science ®Google Scholar
• Fougeroux C, Holst PJ. Future prospects for the development of cost-effective adenovirus vaccines. Int J Mol Sci. 2017 Mar 23;18(4):686.
   Web of Science ®Google Scholar
• Yang Y, Chi Y, Tang X, et al. Rapid, efficient, and modular generation of adenoviral vectors via isothermal assembly. Curr Protoc Mol Biol. 2016 Jan;113(1):16.26.1–16.26.18.
   Google Scholar
• Zhou D, Zhou X, Bian A, et al. An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector. Nat Protoc. 2010 Nov;5(11):1775–1785.
   Web of Science ®Google Scholar
• Horwitz MS. Function of adenovirus E3 proteins and their interactions with immunoregulatory cell proteins. J Gene Med. 2004 Feb;6(Suppl. 1):S172–S183.
   Google Scholar
• Stewart AR, Tollefson AE, Krajcsi P, et al. The adenovirus E3 10.4K and 14.5K proteins, which function to prevent cytolysis by tumor necrosis factor and to down-regulate the epidermal growth factor receptor, are localized in the plasma membrane. J Virol. 1995 Jan;69(1):172–181.
   Web of Science ®Google Scholar
• Guo J, Mondal M, Zhou D. Development of novel vaccine vectors: chimpanzee adenoviral vectors. Hum Vaccin Immunother. 2018 Jul 3;14(7):1679–1685.
   PubMed Web of Science ®Google Scholar
• Bradley RR, Maxfield LF, Lynch DM, et al. Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions. J Virol. 2012 Jan;86(2):1267–1272.
   Web of Science ®Google Scholar
• Sumida SM, Truitt DM, Lemckert AA, et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol. 2005 Jun 1;174(11):7179–7185.
   PubMed Web of Science ®Google Scholar
• Binder AM, Biggs HM, Haynes AK, et al. Human adenovirus surveillance – United States, 2003–2016. MMWR Morb Mortal Wkly Rep. 2017 Oct 6;66(39):1039–1042.
   Web of Science ®Google Scholar
• Kolavic-Gray SA, Binn LN, Sanchez JL, et al. Large epidemic of adenovirus type 4 infection among military trainees: epidemiological, clinical, and laboratory studies. Clin Infect Dis. 2002 Oct 1;35(7):808–818.
   PubMed Web of Science ®Google Scholar
• Lai CY, Lee CJ, Lu CY, et al. Adenovirus serotype 3 and 7 infection with acute respiratory failure in children in Taiwan, 2010–2011. PLoS One. 2013;8(1):e53614.
   Web of Science ®Google Scholar
• Radke JR, Cook JL. Human adenovirus infections: update and consideration of mechanisms of viral persistence. Curr Opin Infect Dis. 2018 Jun;31(3):251–256.
   Web of Science ®Google Scholar
• Yu Z, Zeng Z, Zhang J, et al. Fatal Community-acquired pneumonia in children caused by re-emergent human adenovirus 7d associated with higher severity of illness and fatality rate. Sci Rep. 2016 Nov 16;6:37216.
   PubMed Web of Science ®Google Scholar
• Mao N, Zhu Z, Rivailler P, et al. Multiple divergent human mastadenovirus C co-circulating in mainland of China. Infect Genet Evol. 2019 Dec;76:104035.
   Web of Science ®Google Scholar
• Li J, Lu X, Jiang B, et al. Adenovirus-associated acute conjunctivitis in Beijing, China, 2011–2013. BMC Infect Dis. 2018 Mar 20;18(1):135.
   Google Scholar
• Liu T, Zhou Z, Tian X, et al. A recombinant trivalent vaccine candidate against human adenovirus types 3, 7, and 55. Vaccine. 2018 Apr 12;36(16):2199–2206.
   Web of Science ®Google Scholar
• Qiu H, Li X, Tian X, et al. Serotype-specific neutralizing antibody epitopes of human adenovirus type 3 (HAdV-3) and HAdV-7 reside in multiple hexon hypervariable regions. J Virol. 2012 Aug;86(15):7964–7975.
   Web of Science ®Google Scholar
• Tian X, Jiang Z, Fan Y, et al. A tetravalent vaccine comprising hexon-chimeric adenoviruses elicits balanced protective immunity against human adenovirus types 3, 7, 14 and 55. Antiviral Res. 2018 Jun;154:17–25.
   Web of Science ®Google Scholar
• Bortolanza S, Bunuales M, Alzuguren P, et al. Deletion of the E3-6.7K/gp19K region reduces the persistence of wild-type adenovirus in a permissive tumor model in Syrian hamsters. Cancer Gene Ther. 2009 Sep;16(9):703–712.
   PubMed Web of Science ®Google Scholar
• Wang Y, Hallden G, Hill R, et al. E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat Biotechnol. 2003 Nov;21(11):1328–1335.
   PubMed Web of Science ®Google Scholar
• Liu TC, Wang Y, Hallden G, et al. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus. Gene Ther. 2005 Sep;12(17):1333–1346.
   Web of Science ®Google Scholar
• Maxfield LF, Abbink P, Stephenson KE, et al. Attenuation of replication-competent adenovirus serotype 26 vaccines by vectorization. Clin Vaccine Immunol. 2015 Nov;22(11):1166–1175.
   Google Scholar
• Yeh MT, Bujaki E, Dolan PT, et al. Engineering the live-attenuated polio vaccine to prevent reversion to virulence. Cell Host Microbe. 2020 May 13;27(5):736–751e8.
   PubMed Web of Science ®Google Scholar